- Intel (INTC) shares fell Wednesday after a report said that Nvidia Corp. halted a test to use Intel’s production process to make advanced chips. Nvidia recently tested the so-called 18A process but stopped moving forward, Reuters reported, citing two unidentified people familiar with the matter. Spokespeople for Nvidia and Intel didn’t immediately respond to requests for comment. An Intel spokesperson told Reuters that the company’s 18A manufacturing technologies are “progressing well.”

- Dynavax (DVAX) soared after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.


- Snowflake (SNOW) dipped after The Information reported that the software company is in talks to buy the closely held Observe Inc. for around $1 billion. Baird writes that such a deal “could make strategic sense” as a way to compete with Databricks, which “has been very acquisitive to expand its platform.”

- Intel (INTC) shares fell Wednesday after a report said that Nvidia Corp. halted a test to use Intel&rsquo;s production process to make advanced chips. Nvidia recently tested the so-called 18A process but stopped moving forward, Reuters reported, citing two unidentified people familiar with the matter. Spokespeople for Nvidia and Intel didn&rsquo;t immediately respond to requests for comment. An Intel spokesperson told Reuters that the company&rsquo;s 18A manufacturing technologies are &ldquo;progressing well.&rdquo;
- Dynavax (DVAX) soared after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm&rsquo;s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.
 - Snowflake (SNOW) dipped after The Information reported that the software company is in talks to buy the closely held Observe Inc. for around $1 billion. Baird writes that such a deal &ldquo;could make strategic sense&rdquo; as a way to compete with Databricks, which &ldquo;has been very acquisitive to expand its platform.&rdquo;

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Intel Falls, Dynavax Climbs, Snowflake Slides 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/c21522d4-7ccb-4b82-a3bd-b3bd010651fe/transcript

Advertisement